Tarsus制药（股票代码：TARS）盘前股价大涨7.44%，延续了周三夜盘9.44%的涨幅。这波强劲上涨主要源于公司近期公布的第二季度财报远超市场预期。
根据Tarsus制药发布的财报显示，截至6月30日的第二季度，公司营收同比大幅增长151.5%，达到1.0266亿美元，显著超过分析师预期的9568万美元。尽管公司报告每股亏损48美分，略高于分析师预期的40美分亏损，但相比去年同期88美分的亏损已有明显改善。值得注意的是，公司本季度净亏损为2034万美元，显示出业务正在稳步向盈利迈进。
华尔街分析师对Tarsus制药的前景保持乐观态度。目前，分析师对该公司股票的平均评级为"强力买入"，其中7个评级为"强力买入"或"买入"，1个为"持有"，没有"卖出"或"强力卖出"评级。分析师给出的12个月目标价中位数为72.00美元，较当前股价有约42.8%的上涨空间。这些积极的分析师评级和远高于当前价格的目标价，进一步增强了投资者对Tarsus制药未来发展的信心，推动股价强劲上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.